ChemT CelMo Virtual Cell Platform

ChemT Biotechnology is an AI biotech company based across Singapore and the United States, with a press release datelined Singapore in June 2026. It builds an AI layer for chemistry, manufacturing and controls (CMC) in biologics, addressing low cell yields, high costs and slow trial-and-error in biomanufacturing.

CelMo is an AI Virtual Cell platform trained on proprietary sequencing data and validated in the lab, simulating how cells respond to production conditions and genetic changes. It supports finding target pathways, designing small molecules that guide cell behaviour and AI-assisted cell engineering. Chemplify, its flagship small-molecule product, applies the approach to T-cell manufacturing. The company reports partnerships with 40+ pharma, biotech and CDMO companies.

• CelMo Virtual Cell: models how cells respond to manufacturing conditions and genetic edits.
• Pathway tracking: shows which growth, metabolism and stress processes are activated or suppressed.
• Target identification: finds pathways to improve cell performance.
• AI-designed small molecules: guide cell behaviour to raise productivity and quality.
• Chemplify: small-molecule product for T-cell manufacturing.
• Cell engineering support: AI-assisted engineering planned to extend to stem, NK and HEK cells.

Vietnamese biotech and pharma companies can explore partnerships to improve antibody production cell lines. CDMOs can use the platform to shorten process development. Research institutes working on cell therapy can evaluate small-molecule approaches for T-cell expansion.

Company-reported figures include 50% higher antibody output and 40% shorter production timelines in CHO cells with CelMo, without published baselines. Chemplify is reported to deliver 50% faster development and 60% lower costs in T-cell manufacturing. The approach aims to simplify process development and validation for biologics makers.

Biologics and cell-therapy makers face pressure to cut production cost and timelines. Singapore and the region are building biomanufacturing capacity, creating demand for AI-driven process tools. Vietnam's growing pharmaceutical and biotech sector may seek such partners for bioprocess development.

Based across Singapore and the United States. USD 4 million seed round led by Wavemaker Ventures with SEEDS, Wavemaker 360 Health, Draper University Ventures and Temasek Life Sciences Accelerator, plus USD 1 million angel funding, announced 22 June 2026. The release dates the company at about 18 months old.